BioCardia Seeks Accelerated FDA Path for CardiAMP Cell Therapy in Ischemic Heart Failure

BioCardia, Inc. (NASDAQ: BCDA) has submitted full CardiAMP Heart Failure clinical data to the U.S. Food and Drug Administration and requested a meeting this quarter to discuss a potential accelerated approval pathway. The request focuses on the CardiAMP System for patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF).

The discussion will take place under the therapy’s existing Breakthrough Device Designation. Regulators will evaluate whether BioCardia’s proposed approval package is sufficient based on safety and efficacy data.

Focus on high-risk responder subgroup

The pivotal CardiAMP HF trial did not meet its composite primary endpoint. However, BioCardia is emphasizing a prospectively defined subgroup of ischemic HFrEF patients with elevated heart-stress biomarkers, including NT-proBNP.

In this higher-risk cohort, patients receiving a single endomyocardial dose of autologous CardiAMP cell therapy alongside guideline-directed medical therapy showed:

• 47% relative risk reduction in all-cause cardiac death
• 37% reduction in non-fatal major adverse cardiac events
• Statistically significant quality-of-life improvement (p = 0.04) over two years

Safety data from 125 ischemic HFrEF patients

The upcoming meeting will also review safety outcomes in the full 125-patient ischemic HFrEF population enrolled in the CardiAMP HF study. The therapy was generally well tolerated, with a low incidence of serious procedure-related complications.

BioCardia plans to argue that the biomarker-positive subgroup demonstrates a favorable benefit-risk profile. The company highlights reductions in heart-related mortality equivalents, fewer ventricular arrhythmias, and improvements in cardiac remodeling markers such as left-ventricular volumes and ejection fraction.

Regulatory context and CardiAMP HF II trial

BioCardia notes that the FDA has previously approved high-risk cardiovascular devices despite missed primary endpoints when safety and clinical benefit were demonstrated. The company intends to position CardiAMP within that regulatory precedent.

Meanwhile, the FDA-approved CardiAMP Heart Failure II trial is actively enrolling a refined biomarker-positive population. The study aims to prospectively validate the responder signal. Top-line HF II data are expected around late 2025.

What this means for BCDA investors

For BCDA investors, the requested FDA meeting represents a key binary catalyst. Positive regulatory feedback could accelerate a submission for the high-risk subgroup. Negative feedback would likely shift value realization to the HF II readout.

The development highlights both the upside—potential first-in-class autologous cell therapy for ischemic HFrEF—and the risks tied to regulatory decisions and BioCardia’s funding needs ahead of potential commercialization.